Table 4

 Polysomnographic parameters before and after two weeks of treatment

ParameterBefore melatonin treatment (absolute baseline value)After melatonin treatment (changes in value)
MelatoninPlaceboMelatoninPlacebo
All data are geometric mean (SEM).
NREM, non-rapid eye movement; REM, rapid eye movement; WASO, wakefulness after sleep onset.
No significant differences between the melatonin and placebo groups for any of the absolute baseline scores or after two weeks of treatment.
Time in bed (min)469.40 (17.11)463.88 (16.14)−8.98 (11.75)3.00 (13.37)
Total sleep time (min)342.57 (24.30)357.61 (20.56)31.38 (20.13)29.22 (18.48)
Sleep onset latency (min)51.73 (11.36)34.00 (8.45)−14.97 (7.10)−1.35 (4.91)
NREM (%)82.70 (1.90)84.59 (1.61)−1.48 (1.85)−2.57 (1.70)
Slow wave sleep (%)17.78 (2.33)21.41 (1.67)−0.59 (1.47)−1.55 (1.82)
REM (%)17.29 (1.90)15.42 (1.61)1.49 (1.85)2.54 (1.70)
REM onset latency (min)111.10 (13.41)100.88 (12.70)−20.55 (12.33)−0.30 (13.29)
Sleep efficiency (%)76.97 (3.16)77.66 (4.02)5.44 (2.64)5.55 (3.53)
WASO (min)38.80 (9.34)30.08 (6.19)−9.50 (7.76)−2.93 (7.03)
Arousal index10.13 (1.31)10.22 (1.24)1.03 (1.01)0.85 (1.06)